Document is current
Any future updates will be listed below
-
Authors
Miranda-Cervantes, Adriana https://orcid.org/0009-0009-8170-5101
Fritzen, Andreas M. https://orcid.org/0000-0001-8793-9739
Raun, Steffen H.
Hodek, Ondřej https://orcid.org/0000-0001-8307-9575
Møller, Lisbeth L. V. https://orcid.org/0000-0003-1885-0102
Johann, Kornelia
Deisen, Luisa
Gregorevic, Paul https://orcid.org/0000-0002-7418-8945
Gudiksen, Anders
Artati, Anna
Adamski, Jerzy https://orcid.org/0000-0001-9259-0199
Andersen, Nicoline R.
Sigvardsen, Casper M. https://orcid.org/0000-0002-9891-5721
Carl, Christian S. https://orcid.org/0000-0002-9551-5837
Voldstedlund, Christian T. https://orcid.org/0000-0002-6368-8995
Kjøbsted, Rasmus https://orcid.org/0000-0002-0628-4994
Hauck, Stefanie M. https://orcid.org/0000-0002-1630-6827
Schjerling, Peter
Jensen, Thomas E. https://orcid.org/0000-0001-6139-8268
Cebrian-Serrano, Alberto https://orcid.org/0000-0002-4737-0215
Jähnert, Markus https://orcid.org/0000-0001-6459-7318
Gottmann, Pascal https://orcid.org/0000-0002-9791-783X
Burtscher, Ingo
Lickert, Heiko https://orcid.org/0000-0002-4597-8825
Pilegaard, Henriette https://orcid.org/0000-0002-1071-0327
Schürmann, Annette https://orcid.org/0000-0002-4113-4377
Tschöp, Matthias H. https://orcid.org/0000-0002-4744-371X
Moritz, Thomas https://orcid.org/0000-0002-4258-3190
Müller, Timo D. https://orcid.org/0000-0002-0624-9339
Sylow, Lykke https://orcid.org/0000-0003-0905-5932
Kiens, Bente https://orcid.org/0000-0001-5705-5625
Richter, Erik A. https://orcid.org/0000-0002-6850-3056
Kleinert, Maximilian https://orcid.org/0000-0002-8069-9055
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF18CC0034900, NNF19OC0055192)
Det Frie Forskningsråd (2030-00007A)
Deutsche Forschungsgemeinschaft (DFG TRR296, TRR152, SFB1123)
- License Information
-
More Information
Article History
Received: 13 July 2023
Accepted: 26 November 2024
First Online: 2 January 2025
Competing interests
: M.H.T. delivered a scientific lecture for Böhringer Ingelheim Pharma GmbH & Co. KG (2024), AstraZeneca GmbH (2024), Lilly Deutschland GmbH (2024) and Novo Nordisk Pharma GmbH (2024). He is co-founder of the biotech startups Ghrelco and Bluewater Biotech (2024). As CEO and CSO of Helmholtz Munich, M.H.T. is co-responsible for countless collaborations of the employees with a multitude of companies and institutions, worldwide. In this capacity, he discusses potential projects with and has signed/signs contracts for the centers institute(s) related to research collaborations worldwide, including but not limited to pharmaceutical corporations like Boehringer Ingelheim, Novo Nordisk, Roche Diagnostics, Arbormed, Eli Lilly, SCG Cell Therapy and others. As the CEO of Helmholtz Munich, he was/is further overall responsible for commercial technology transfer activities. M.H.T. confirms that to the best of his knowledge none of the above funding sources or collaborations were involved in or had an influence on the preparation of this manuscript. The remaining authors declare no competing interests.
